coin based currency- Top See results about

Huadong Pharmaceutical has established a new company in Jiaxing with a registered capital of 60 million yuan. According to Tianyancha App, Huadong Pharmaceutical (Jiaxing) Co., Ltd. was recently established with Zhu Li as its legal representative and a registered capital of 60 million yuan. Its business scope includes drug wholesale, drug retail, decoction service for Chinese herbal pieces, third-class medical device operation, drug Internet information service, drug import and export, third-class medical device rental and medical device Internet information service. According to shareholder information, the company is wholly owned by Huadong Pharmaceutical (000963).China Chengtong and China Yizhong set up an enterprise management center with a capital contribution of 6.25 billion yuan. According to Tianyancha App, Zhongcheng (Beijing) Enterprise Management Center (Limited Partnership) was recently established. The executive partner is Yizhong Group Sunac Technology Development Co., Ltd., with a capital contribution of 6.25 billion yuan. The business scope is enterprise management and enterprise management consulting. It is owned by China Chengtong's Beijing Chengtong Capital Investment Co., Ltd., China Yizhong Group Co., Ltd. and its subsidiary Sunac Technology Development Co., Ltd.The OpenAI webpage shows that API, ChatGPT and Sora are all running normally.

Interbank certificates of deposit funds are popular. In the context of the current downward trend of non-bank interbank deposit rates, interbank deposit rates are relatively more attractive, and interbank deposit funds have recently gained popularity. Since December, the 7-day holding fund of AAA index of China Securities Interbank Deposits issued by BlackRock Fund and Agricultural Bank of China Credit Suisse Fund has reached the upper limit of 5 billion yuan, and triggered proportional placement. Both funds are partially confirmed by the principle of "doomsday ratio confirmation", and the doomsday confirmation ratio is 73.36% and 27.02% respectively. In addition, Huatai Bairui Fund and China-Canada Fund also imposed subscription restrictions on their 7-day holding funds of the AAA Index of China Securities Interbank Deposits. From December 11th, the amount of multiple cumulative subscriptions (including conversion and fixed investment) for a single fund account of Huatai Bairui CSI Interbank Deposit Certificate AAA Index 7-day holding fund shall not exceed 100,000 yuan; From December 6th, the subscription amount of a single investor of the 7-day holding fund of China-Canada CSI Interbank Deposit Certificate AAA Index will not exceed 10 million yuan (except for individual investors and public asset management products). (CSI Taurus)Guangxi: In November, 23,774 cases of legal infectious diseases were reported and 320 people died. The Health and Health Commission of Guangxi Zhuang Autonomous Region announced the epidemic situation of legal infectious diseases in Guangxi in November 2024. No cases of Class A infectious diseases were reported. 14,775 cases of Class B infectious diseases were reported, with 320 deaths. The reported diseases include AIDS, viral hepatitis, rabies, dengue fever, dysentery, tuberculosis, typhoid plus paratyphoid, whooping cough, scarlet fever, brucellosis, gonorrhea, syphilis, leptospirosis, malaria, novel coronavirus infection and monkeypox. The top five reported cases were viral hepatitis, tuberculosis, syphilis, AIDS and gonorrhea, accounting for 94.34% in total. 8999 cases of Class C infectious diseases were reported, with no death. The reported diseases include influenza, mumps, rubella, acute hemorrhagic conjunctivitis, leprosy, typhus, other infectious diarrhea and hand, foot and mouth disease. The top three reported cases were other infectious diarrhea, hand-foot-mouth disease and influenza, accounting for 91.43% in total.Aviation Materials Co., Ltd. released the Procurement Project of Feasibility Study Report of Beijing Aviation Materials Research Institute Co., Ltd., and China Hangfa Online Mall released the Project of Feasibility Study Report of Beijing Aviation Materials Research Institute Co., Ltd.. The publishing unit is Beijing Institute of Aeronautical Materials Co., Ltd. (Aeronautical Materials Co., Ltd., 688563). Services include: feasibility study report of equity acquisition project; Feasibility study report on technology patent acquisition.

Aviation Materials Co., Ltd. released the Procurement Project of Feasibility Study Report of Beijing Aviation Materials Research Institute Co., Ltd., and China Hangfa Online Mall released the Project of Feasibility Study Report of Beijing Aviation Materials Research Institute Co., Ltd.. The publishing unit is Beijing Institute of Aeronautical Materials Co., Ltd. (Aeronautical Materials Co., Ltd., 688563). Services include: feasibility study report of equity acquisition project; Feasibility study report on technology patent acquisition.CEO of Bank of America: The sales and trading business is expected to reach a new high in the fourth quarter, and the investment banking business income will jump. On December 11th, the CEO of Bank of America Brian moynihan said that with the "continuous growth" of transactions, the bank's investment banking business income in the fourth quarter may exceed US$ 1.4 billion, with a year-on-year increase of at least 25%. Moynihan also said that the sales and trading business in the fourth quarter should record a year-on-year growth again, achieving a medium-to-high single-digit growth. The bank also expects that the net interest income will continue to grow, which is expected to achieve the guiding target of $14.3 billion given earlier this year.In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for the replacement of generic drugs. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)